Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients
- 22 November 2019
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 59 (5) , 277-285
Abstract
Neuroblastoma (NB) is the most common extracranial malignant tumor of childhood and is characterized by a broad heterogeneity in clinical presentation and evolution. Recent advances in pangenomic analysis of NB have revealed different recurrent chromosomal aberrations. Indeed, it is now well established that the overall genomic profile is important for treatment stratification. In previous studies, 11 genes were shown to be recurrently amplified (ODC1, ALK, GREB1, NTSR2, LIN28B, MDM2, CDK4, MYEOV, CCND1, TERT, and MYC) besides MYCN, with poor survival of NB patients harboring these amplifications being suggested. Genomic profiles of 628 NB samples analyzed by array‐comparative genome hybridization (a‐CGH) were re‐examined to identify gene amplifications other them MYCN amplification. Clinical data were retrospectively collected. We additionally evaluated the association of FRS2 gene expression with NB patient outcome using the public R2 Platform. We found eight NB samples with high grade amplification of one or two loci on chromosome arm 12q. The regional amplifications were located on bands 12q13.3‐q14.1 and 12q15‐q21.1 involving the genes CDK4, MDM2, and the potential oncogenic gene FRS2. The CDK4, MDM2, and FRS2 loci were coamplified in 8/8 samples. The 12q amplifications were associated with very poor prognosis and atypical clinical features of NB patients. Further functional and clinical investigations are needed to confirm or refute these associations.Keywords
This publication has 43 references indexed in Scilit:
- NeuroblastomaNature Reviews Disease Primers, 2016
- Neuroblastoma: Molecular Pathogenesis and TherapyAnnual Review of Medicine, 2015
- Neuroblastoma: developmental biology, cancer genomics and immunotherapyNature Reviews Cancer, 2013
- Association of Age at Diagnosis and Genetic Mutations in Patients With NeuroblastomaJAMA, 2012
- Accumulation of Segmental Alterations Determines Progression in NeuroblastomaJournal of Clinical Oncology, 2010
- Overall Genomic Pattern Is a Predictor of Outcome in NeuroblastomaJournal of Clinical Oncology, 2009
- Characterization of amplicons in neuroblastoma: High‐resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genesGenes, Chromosomes and Cancer, 2008
- High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arraysCancer Genetics and Cytogenetics, 2007
- High‐resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray‐based comparative genomic hybridizationGenes, Chromosomes and Cancer, 2004
- Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastomaGenes, Chromosomes and Cancer, 2003